

**KERN HEALTH SYSTEMS’  
dba KERN FAMILY HEALTH CARE  
September 28, 2005 at 6:30 pm  
MEETING OF THE  
PHARMACY AND THERAPEUTICS  
COMMITTEE  
AGENDA**

---

**Hodel’s Restaurant,  
5917 Knudsen Drive (Hwy 99 and Olive Drive)  
Bakersfield, Ca. 93308**

**The Agenda is divided into three sections:**

**CORRESPONDENCE AND CONSENT CALENDAR:** These matters include routine non-policy financial and administrative actions, may include correspondence, and are usually approved by a single majority vote. Any Committee Member may remove an item from the correspondence and consent calendar.

**REGULAR CALENDAR:** These items include significant financial, administrative and policy matters.

**CLOSED SESSION:** These items include contracting, peer review, personnel and litigation matters and other issues to be discussed by Committee members only, with report to the public on any action taken.

**REGULAR AGENDA**

**CORRESPONDENCE AND CONSENT CALENDAR**

1. Approval of the minutes from the June 29, 2005 Pharmacy and Therapeutics meeting.
2. The following items were approved at the August 11<sup>th</sup> Board of Directors meeting.
  1. Recommended additions to the Formulary:
    - a. Spironolactone
    - b. Ranitidine
  2. New additions to the formulary:
    - a. ~~Fenofibrate (attachment)~~ – **PULLED OFF AGENDA**
    - b. Phenergan (Promethazine: DM, Codeine, VC) (attachment)
    - c. Singulair (Montelukast) (attachment)

## REGULAR CALENDAR

### I. PUBLIC COMMENT

This portion of the meeting is reserved for persons to address the Committee on any matter not on this agenda but under the jurisdiction of the Committee. They may ask a question for clarification, make a referral to staff for factual information or request staff to report back to the Committee at a later meeting.

Also, the Committee may take action to direct the staff to place a matter of business on a future agenda.

**SPEAKERS ARE LIMITED TO TWO MINUTES. PLEASE  
STATE YOUR NAME BEFORE MAKING YOUR  
PRESENTATION. THANK YOU!**

### II. Action Items

Discussion and Possible Action Regarding Formulary Changes

#### A. Update –

1. DUR:
  - a. general
  - b. Antibiotic benchmarking
2. Medicare

#### B. Diabetes Management

1. Byetta
2. Thiazolidinediones
3. Test strips/supplies

#### C. Vigamox utilization review

#### D. Anticonvulsants dosing/utilization review

### III. Adjournment

**Tentative next regular meeting January, 2006**

---

PLEASE NOTE: Anyone wishing information on the Kern Health Systems Pharmacy & Therapeutics Committee Agendas should contact Bruce Wearda, R.Ph., Corporate Pharmacist, at Kern Health Systems either by telephone at (661)664-5100 or in writing at the following address:

Kern Health Systems  
9700 Stockdale Hwy  
Bakersfield, CA 93311

Such requests must be received no later than 5:00 p.m. ten (10) calendared days prior to the next regularly scheduled Committee Meeting.